Immunity and Pathogenesis Program

Disease and the immune response

Pathogenesis—literally how disease (pathos) begins (genesis) or develops—is a broad and important area of research.

Many diseases can arise from pathogens, but the immune system protects us through various lines of defense. If the immune system fails to function properly and becomes too weak or too strong, it can lead to disease states that include immunodeficiencies that lead to enhanced susceptibly to infections disease, autoimmune conditions, such as lupus and arthritis, and even cancer.

Director's statement

Our focus is on understanding the regulation and interplay of host immune responses and microbial pathogenesis. We study pathogen-host interactions, innate and humoral immunity, inflammation and T cell checkpoint regulation. A better understanding of these aspects of the immune system will provide novel therapeutic opportunities to address many unmet medical needs, including the treatment of endemic and pandemic infectious diseases, autoimmune disorders, cancer and inflammatory diseases.

– Jamey Marth , Ph.D., Program Director

Appointments

Publications

Realigning the LIGHT signaling network to control dysregulated inflammation.

Ware CF, Croft M, Neil GA

J Exp Med 2022 Jul 4 ;219(7)

Shared and Unique Evolutionary Trajectories to Ciprofloxacin Resistance in Gram-Negative Bacterial Pathogens.

Zlamal JE, Leyn SA, Iyer M, Elane ML, Wong NA, Wamsley JW, Vercruysse M, Garcia-Alcalde F, Osterman AL

mBio 2021 Jun 29 ;12(3):e0098721

Sphingosine 1-phosphate escapes the Catch-22 of sepsis prevention and mitigation therapies.

Blaho VA

EBioMedicine 2020 Sep ;59:102952

COG4 mutation in Saul-Wilson syndrome selectively affects secretion of proteins involved in chondrogenesis in chondrocyte-like cells.

Xia ZJ, Mahajan S, Paul Daniel EJ, Ng BG, Saraswat M, Campos AR, Murad R, He M, Freeze HH

Front Cell Dev Biol 2022 ;10:979096

SARS-CoV-2 infects human brain organoids causing cell death and loss of synapses that can be rescued by treatment with Sofosbuvir.

Mesci P, de Souza JS, Martin-Sancho L, Macia A, Saleh A, Yin X, Snethlage C, Adams JW, Avansini SH, Herai RH, Almenar-Queralt A, Pu Y, Szeto RA, Goldberg G, Bruck PT, Papes F, Chanda SK, Muotri AR

PLoS Biol 2022 Nov ;20(11):e3001845

Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity.

Pohl MO, Martin-Sancho L, Ratnayake R, White KM, Riva L, Chen QY, Lieber G, Busnadiego I, Yin X, Lin S, Pu Y, Pache L, Rosales R, Déjosez M, Qin Y, De Jesus PD, Beall A, Yoh S, Hale BG, Zwaka TP, Matsunaga N, García-Sastre A, Stertz S, Chanda SK, Luesch H

ACS Infect Dis 2022 Jul 8 ;8(7):1265-1279

Synthetic lethality-based prediction of anti-SARS-CoV-2 targets.

Pal LR, Cheng K, Nair NU, Martin-Sancho L, Sinha S, Pu Y, Riva L, Yin X, Schischlik F, Lee JS, Chanda SK, Ruppin E

iScience 2022 May 20 ;25(5):104311

Btla signaling in conventional and regulatory lymphocytes coordinately tempers humoral immunity in the intestinal mucosa.

Stienne C, Virgen-Slane R, Elmén L, Veny M, Huang S, Nguyen J, Chappell E, Balmert MO, Shui JW, Hurchla MA, Kronenberg M, Peterson SN, Murphy KM, Ware CF, Šedý JR

Cell Rep 2022 Mar 22 ;38(12):110553

NFAM1 Promotes Pro-Inflammatory Cytokine Production in Mouse and Human Monocytes.

Juchem KW, Gounder AP, Gao JP, Seccareccia E, Yeddula N, Huffmaster NJ, Côté-Martin A, Fogal SE, Souza D, Wang SS, Glynn ERA, Yung I, Ritchie J, Li L, Zheng J, Mbow ML, Li J, Chanda SK

Front Immunol 2021 ;12:773445

Show All Publications